Augmentation strategies for therapy resistant depression - A review;Augmentationsstrategien bei therapieresistenz auf antidepressiva

Psychiatrische Praxis

Volumn 34, Issue 4, 2007, Pages 165-174

  Schmauß, Max ^a   Messer, Thomas ^a  

^a Bezirkskrankenhaus Augsburg   (Germany)

Author keywords

Augmentation strategies; Refractory depression; Therapy resistant depression

Indexed keywords

AMITRIPTYLINE; BUSPIRONE; DOPAMINE RECEPTOR STIMULATING AGENT; IMIPRAMINE; LITHIUM; MODAFINIL; PINDOLOL; PLACEBO; RESERPINE; TRICYCLIC ANTIDEPRESSANT AGENT;

CLINICAL PRACTICE; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; REVIEW;

EID: 34250337233     PISSN: 03034259     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-940058     Document Type: Review

References (153)

1. Amsterdam JD, Hornig-Rohan M. Treatment algorithms in treatment-resistant depression. Psychiatr Clin North Am 1996; 19: 371-386
2. Fawcett J. Progress in treatment-resistant and treatment-refractory depression: we still have a long way to go. J Clin Psychiatry 1994; 24: 214-216
3. Nierenberg AA, Amsterdam JD. Treatment-resistant depression: definition and treatment approaches. J Clin Psychiatry 1990; 51 (Suppl 6): 39-47
4. Guscott R, Grof P. The clinical meaning of refractory depression: a review for the clinician. Am J Psychiatry 1991; 148: 695-704
5. Laux G. Chronifizierte Depressionen. Stuttgart: Enke, 1986
6. Schmauß M, Meller I. Die "therapieresistente" Depression - Ursachen und Behandlungsmoglichkeiten. Psychiat Prax 1989; 16: 101-108
7. Kielholz P, Terzani S, Gastpar M. Behandlung der therapieresistenten Depressionen. Dtsch Med Wochenschr 1978; 103: 241-243
8. Pöldinger W, Alac S, Krebs-Roubicek E. Zur Behandlung therapiere-fraktärer Depressionen. In: Kielholz P, Adams C: Antidepressive Infusionstherapie. Stuttgart: Thieme, 1982
9. Möller HJ. Therapieresistenz auf Antidepressiva: Risikofaktoren und Behandlungsmoglichkeiten. Nervenarzt 1991; 62: 658-669
10. Stern SL, Mendels J. Drug combinations in the treatment of refractory depression: a review. J Clin Psychiatry 1981; 42: 368-373
11. Nolen WA, Haffmans J. Treatment of resistant depression. Review on the efficacy of various biological treatments, specifically in major depression resistant to cyclic antidepressants. Intern Clin Psychopharmacol 1989; 4: 217-228
12. Helmchen H. Gestuftes Vorgehen bei Resistenz gegen Antidepressiva-Therapie. In: Möller HJ: Therapieresistenz unter Antidepressivabehandlung. Berlin, Heidelberg, New York: Springer, 1990: 237-250
13. Nierenberg AA, White K. What next? A review of pharmacologic strategies for treatment resistant depression. Psychopharmacol Bull 1990; 26: 429-460
14. Möller HJ. Non-response to antidepressants: risk factors and therapeutic possibilities. Clin Psychopharmacol 1994; 9 (Suppl 2): 17-23
15. Möller HJ. Therapieresistenz auf Antidepressiva. Nervenarzt 2004; 75: 499-517
16. Möller HJ. Medikamentöse Therapiestrategien bei therapieresistenter unipolarer Depression. Psychopharmakotherapie 2004; 11: 34-41
17. Bauer M, Whybrow PC. Thyroid hormone, neural tissue and mood modulation. World J Biol Psychiatry 2001; 2: 57-67
18. Joffe RT, Sokolov ST. Thyroid hormones, the brain, and affective disorders. Crit Rev Neurobiol 1994; 8: 45-63
19. Baumgartner A. Schilddrüsenhormone und depressive Erkrankungen. Teil I. Nervenarzt 1993; 64: 1-10
20. Wilson IC, Prange AJ, McClane TK et al. Thyroid-hormone enhancement of imipramine in nonretarded depressions. N Eng J Med 1970; 282: 1063-1067
21. Coppen A, Whybrow PC, Noguera R et al. The comparative antidepressant value of L-tryptophan and imipramine with and without attempted potentiation by liothyronine. Arch Gen Psychiatry 1972; 26: 234-241
22. Earle BV. Thyroid hormone and tricyclic antidepressants in resistant depressions. Am J Psychiatry 1970; 126: 1667-1669
23. Schwarcz G, Halaris A, Baxter D et al. Normal thyroid function in desipramine nonresponders converted to responders by the addition of L-triiothyronine. Am J Psychiatry 1984; 141: 1614-1616
24. Targum SD, Greenberg RD, Harmon RL et al. Thyroid hormone and the TRH stimulation test in refractory depression. J Clin Psychiatry 1984; 45: 345-346
25. Ogura C, Okuma T, Uchida Y, Imai S. Combined thyroid (triiodothyronine)- tricyclic antidepressant treatment in depressive states. Folia Psychiatr Neurol Jpn 1974; 28: 179-186
26. Banki CM. Cerebrospinal fluid amine metabolites after combined amitriptyline-triiodothyronine treatment of depressed women. Eur J Clin Pharmacol 1977; 11: 311-315
27. Tsutsui S, Yamazaki Y, Namba T, Tsushima M. Combined therapy of T3 and antidepressants in depression. J Int Med Res 1979; 7: 138-146
28. Extein J. Case reports of l-triiodothyronine potentiation. Am J Psychiatry 1982; 139: 966-967
29. Joffe RT. Triiodothyronine potentiation of the antidepressant effect of phenelzine. J Clin Psychiatry 1988; 49: 409-410
30. Goodwin FK, Prange AJ, Post RM et al. A potentiation of antidepressant effect by l-triiotdothyronine in tricyclic nonresponders. Am J Psychiatry 1982; 139: 34-38
31. Joffe RT, Singer W. A comparison of triiodothyronine and thyroxine in the potentiation of tricyclic antidepressants. Psychiatry Res 1990; 32: 241-251
32. Garbutt JC, Mayo JP, Gillette GM et al. Lithium potentiation of tricyclic antidepressants following lack of T3 potentiation. Am J Psychiatry 1986; 143: 1038-1039
33. Thase ME, Kupfer DJ, Jarrett DB. Treatment of imipramine-resistant recurrent depression: I. An open clinical trial of adjunctive L-triiodothyronine. J Clin Psychiatry 1989; 50: 385-388
34. Feighner JP, King LJ, Schuckit MA et al. Hormonal potentiation of imipramine and ECT in primary depression. Am J Psychiatry 1972; 128: 1230-1238
35. Birkenhäger TK, Vegt M, Nolen WA. An open study of triiodothyronine augmentation of tricyclic antidepressants in inpatients with refractory depression. Pharmacopsychiatry 1997; 30: 23-26
36. Kirkegaard C, Bjorum N, Cohn D, Lauridsen UB. Thyrotropin- releasing hormone (TRH) stimulation test in manic depressive illness. Arch Gen Psychiatry 1978; 35: 1017-1021
37. Gitlin MJ, Weiner H, Fairbanks L et al. Failure of T3 to potentiate tricyclic antidepressant response. J Affective Disord 1987; 13: 267-272
38. Stern RA, Nevels CT, Shelhorse ME et al. Antidepressant and memory effects of combined thyroid hormone treatment and electroconvulsive therapy: preliminary findings. Biol Psychiatry 1991; 30: 623-627
39. Joffe RT, Singer W, Levitt AJ, MacDonald C. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 1993; 50: 387-393
40. Joffe RT, Lewitt AJ, Bagby RM et al. Predictors of response to lithium and triiodothyronine augmentation of antidepressants in tricyclic nonresponders. Br J Psychiatry 1993; 163: 574-578
41. Aronson R, Offman HJ, Joffe RT et al. Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch Gen Psychiatry 1996; 53: 842-848
42. Bauer M, Hellweg R, Gräf KJ, Baumgartner A. Treatment of refractory depression with high-dose thyroxine. Neuropsychopharmacology 1998; 18: 444-445
43. Stein D, Avni J. Thyroid hormones in the treatment of affective disorders. Acta Psychiatr Scand 1988; 77: 623-636
44. Joffe RT, Roy-Byrne PP, Uhde TW, Post RM. Thyroid function and affective illness: A reappraisal. Biol Psychiatry 1984; 19: 1685-1691
45. Prange AJ jr, Wilson IC, Breese GR, Lipton MA. Hormonal alteration of imipramine response: a review. In: Sachar EJ: Hormones, behavior, and psychopathology. New York: Raven, 1976
46. Whybrow PC, Prange AJ jr. A hypothesis of thyroid-catecholamine receptor interaction. Arch Gen Psychiatry 1981; 38: 106-113
47. Wheatley D. Potentiation of amitriptyline by thyroid hormone. Arch Gen Psychiatry 1972; 26: 229-233
48. Burckhardt C, Raeder E, Müller V et al. Cardiovascular effects of tricyclic and tetracyclic antidepressants. J Am Med Assoc 1978; 239: 213-216
49. Hoffman L, Lowery R. The electrocardiogram in thyrotoxicosis. Am J Cardiology 1960; 6: 893-904
50. Breese GR, Taylor TD, Prange AJ jr. The effects of triiodothyronine on the disposition and actions of imipramine. Psychopharmacologia 1972; 25: 101-111
51. Worral EP, Moody JP, Peet M et al. Controlled studies of the acute antidepressant effects of lithium. Br J Psychiatry 1979; 135: 255-262
52. Johnson GF. Lithium in depression: a review of the antidepressant and prophylactic effects of lithium. Aust NZJ Psychiat 1987; 21: 356-365
53. Montigny C de, Grunberg F, Mayer A, Deschenes JP. Lithium induces rapid relief of depression in tricyclic-antidepressant drug non-responders. Br J Psychiatry 1981; 138: 252-256
54. Price LH. Lithium augmentation in tricyclic resistant depression. In: Extein I: Treatment of Tricyclic Resistant Depression. Washington DC: American Psychiatric Press, 1988
55. Schöpf J. Lithiumzugabe zu Thymoleptika als Behandlung therapie-resistenter Depressionen. Nervenarzt 1989; 60: 200-205
56. Schou M. Lithium and treatment resistant depression: A review. Lithium 1990; 1: 3-8
57. Austin MPV, Souza FGM, Goodwin GM. Lithium augmentation in anti-depressant-resistant patients. A quantitative analysis. Br J Psychiatry 1991; 159: 510-514
58. Montigny C de. Lithium addition in treatment resistant depression. Intern Clin Psychopharmacol 1994; 9, Suppl 2: 31-35
59. Montigny C de, Cournoyer C, Morissette R et al. Lithium carbonate in tricyclic antidepressant-resistant unipolar depression. Arch Gen Psychiatry 1983; 40: 1327-1334
60. Price LH, Charney DS, Heninger GR. Variability of response to lithium augmentation in refractory depression. Am J Psychiatry 1986; 143: 1387-1392
61. Thase ME, Kupfer DJ, Frank E, Janet DB. Treatment of imipramine resistant recurrent depression II. An open clinical trial of lithium augmentation. J Clin Psychiatry 1989; 50: 413-417
62. Zimmer B, Rosen J, Thornton JE et al. Adjunctive lithium carbonate in nortriptyline resistant elderly depressed patients. J Clin Psychopharmacol 1991; 11: 254-256
63. Flint AJ, Rifat SL. A prospective study of lithium augmentation in antidepressant resistant geriatric depression. J Clin Psychopharmacol 1994; 14: 353-356
64. Bauer M, Döpfmer S. Lithium augmentation in treatment-resistant depression - A meta-analysis of placebo-controlled studies. J Clin Psychopharmacol 1999; 19: 427-434
65. Kantor D, McNevin S, Leichner P et al. The benefit of lithium carbonate adjunct in refractory depression - fact or fiction? Can J Psychiatry 1986; 3: 416-418
66. Zusky PM, Biederman J, Rosenbaum JF et al. Adjunct low dose lithium carbonate in treatment-resistant depression: a placebo-controlled study. J Clin Psychopharmacol 1988; 8: 120-124
67. Stein G, Bernadt M. Lithium augmentation therapy in tricyclic resistant depression. A controlled trial using lithium in low and normal doses. Br J Psychiatry 1993; 162: 634-640
68. Heninger GR, Charney DS, Sternberg DE. Lithium carbonate augmentation of antidepressant treatments. Arch Gen Psychiatry 1983; 40: 1335-1342
69. Cournoyer G, Montigny C de, Quellette J et al. Lithium addition in tricyclic-resistant unipolar depression: a placebo-controlled study. Florence, Italy: Abstracts CINP, 1984, 19-23: 179
70. Schöpf J, Baumann P, Lemarchand T, Rey M. Treatment of endogenous depressions resistant to tricyclic antidepressants or related drugs by lithium addition: results of a placebo-controlled double-blind study. Pharmacopsychiatry 1989; 22: 183-187
71. Katona CLE, Abou-Saleh MT, Harrison DA et al. Placebo controlled trial of lithium augmentation of fluoxetine and lofepramine. Br J Psychiatry 1995; 166: 80-86
72. Fava M, Rosenbaum JF, Mc Grath PJ et al. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: A double blind controlled study. Am J Psychiatry 1994; 151: 1372-1374
73. Baumann P, Nil R, Souche A et al. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. J Clin Psychopharmacol 1996; 16: 307-314
74. Dinan TG, Barry S. A comparison of electroconvulsive therapy with a combined lithium and tricyclic combination among depressed tricyclic nonresponders. Acta Psychiatr Scand 1989; 80: 97-100
75. Price LH, Conwell Y, Nelson JC. Lithium augmentation of combined neuroleptic-tricyclic treatment in delusional depression. Am J Psychiatry 1983; 140: 318-322
76. Weaver KEC. Lithium for delusional depression. Am J Psychiatry 1983; 140: 962-963
77. Pai M, White AC, Deance AG. Lithium augmentation in the treatment of delusional depression. Br J Psychiatry 1986; 148: 736-738
78. Nelson JC, Mazure CM. Lithium augmentation in psychotic depression refractory to combined drug treatment. Am J Psychiatry 1986; 143: 363-366
79. Joffe RT. T3 and lithium potentiation of tricyclic antidepressants. Am J Psychiat 1988; 145: 1317-1318
80. Garbutt JC, Malekpour M, Brunswick D et al. Effects of triiodothyronine on drug levels and cardiac function in depressed patients treated with imipramine. Am J Psychiatry 1979; 136: 980-982
81. Ontiveros A, Fontaine R, Elie R. Refractory depression: the addition of lithium to fluoxetine or desipramine. Acta Psychiatr Scand 1991; 83: 188-192
82. Lingjaerde O, Edlund AH, Gormsen CA et al. The effect of lithium carbonate in combination with tricyclic antidepressants in endogenous depression. Acta Psychiatr Scand 1974; 50: 233-242
83. Price LH, Charney DS, Heninger GR. Efficacy of lithium-tranylcypromine treatment in refractory depression. Am J Psychiat 1985; 142: 619-623
84. Madakasira S. Low dose potency of lithium in antidepressant augmentation. Psychiatr J Univ Ottawa 1986; 11: 107-109
85. Dinan TG. Lithium augmentation in sertraline resistant depression: A preliminary dose-response study. Acta Psychiat Scand 1993; 88: 300-301
86. Montigny C de, Elie R, Caillé G. Rapid response to the addition of lithium in iprindole-resistant unipolar depression: a pilot study. Am J Psychiatry 1985; 142: 220-223
87. Zullino D, Baumann P. Lithium augmentation in depressive patients not responding to selective serotonin reuptake inhibitors. Pharmacopsychiatry 2001; 34: 119-127
88. Cowen PJ, Mc Cance SL, Ware CJ et al. Lithium in tricyclic resistant depression correlation of increased brain 5 HT function with clinical outcome. Br J Psychiatry 1991; 159: 341-346
89. Nelson JC, Bowers MB jr. Delusional unipolar depression. Arch Gen Psychiatry 1978; 35: 1321-1328
90. Kaskey GB, Nasr S, Meltzer HY. Drug treatment in delusional depression. Psychiat Res 1980; 1: 267-277
91. Rothschild AJ, Samson JA, Bessette MP et al. Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression. J Clin Psychiatry 1994; 54: 338-342
92. Matthews JD, Bottonari K, Polania LM. An open study of olanzapine and fluoxetine for psychotic major depressive disorder: interim analyses. J Clin Psychiatry 2002; 63: 1164-1170
93. Rothschild AJ, Douglas JW, Tohen MF et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. J Clin Psychopharmacology 2004; 24: 365-373
94. Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry 1999; 60: 256-259
95. Marangell LB, Johnson CR, Kertz B et al. Olanzapine in the treatment of apathy in previously depressed participants maintained with selective serotonin reuptake inhibitors: an open-label, flexible-dose study. J Clin Psychiatry 2002; 63: 391-395
96. Adson DE, Kushner MG, Eiben KM, Schulz SC. Preliminary experience with adjunctive quetiapine in patients receiving selective serotonin reuptake inhibitors. Depression and Anxiety 2004; 19: 121-126
97. Papakostas GI, Petersen TJ, Nierenberg AA et al. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant depressive disorder. J Clin Psychiatry 2004; 65: 217-221
98. Shelton RC. The combination of olanzapine and fluoxetine in mood disorders. Expert Opin Pharmacother 2003; 4: 1175-1183
99. Shelton RC, Tollefson GD, Tohen M et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001; 158: 131-134
100. th Annual Meeting of the APA, May 1- 6 2004
101. th Annual Meeting of the APA, May 17-22 2003
102. Oppenheim G. Estragen in the treatment of depression: neuropharmacological mechanisms. Biol Psychiatry 1983; 18: 721-725
103. Shapira B, Oppenheim G, Zoher J et al. Lack of efficacy of estrogen supplementation to imipramine in resistant female depressives. Biol Psychiatry 1985; 20: 576-579
104. Sherwin BB. Estrogen and refractory depression. In: Amsteram JD: Advances in Neuropsychiatry and Psychopharmacology, Vol 2: Refractory Depression. New York: Raven, 1991: 209-218
105. Flemenbaum A. Methylphenidate: A catalyst for the tricyclic antidepressants. Am J Psychiatry 1971; 128: 239
106. Chiarello RJ, Cole JO. The use of psychostimulants in general psychiatry. Arch Gen Psychiatry 1987; 44: 286-295
107. Fawcett J, Kravietz HM, Zajecka MR. CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression. J Clin Psychopharmacol 1991; 11: 127-132
108. Stoll AL, Pillay SS, Diamond L et al. Methylphenidate augmentation of serotonin selective reuptake inhibitors: a case series. J Clin Psychiatry 1996; 57: 72-76
109. Bader G, Hawley JM, Short DD. Venlafaxine augmentation with methylphenidate for treatment-refractory depression: a case report. J Clin Psychopharmacol 1998; 18: 255-256
110. Linet LS. Treatment of a refractory depression with a combination of fluoxetine and d-amphetamine (letter). Am J Psychiat 1989; 146: 803-804
111. Gupta S, Ghaly N, Dewan M. Augmenting fluoxetine with dextroamphetamine to treat refractory depression. Hosp Com Psychiat 1992; 43: 281-283
112. Warneke L. Psychostimulants in psychiatry. Can J Psychiatry 1990; 35: 3-10
113. McClellan KJ, Spencer CM. Modafinil - a review of its pharmacology and clinical efficacy in the management of narcolepsy. CNS Drugs 1998; 9: 311-324
114. Menza MA, Kaufman KR, Castellanos A. Modafinil augmentation of antidepressant treatment in depression. J Clin Psychiatry 2000; 61: 378-381
115. DeBattista C, Doghramji K, Menza M et al. Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. J Clin Psychiatry 2003; 64: 1057-1064
116. Markovitz P, Wagner S. An open-label trial of modafinil augmentation in patients with partial response to antidepressant therapy. J Clin Psychopharmacol 2003; 23: 1-3
117. Kaufman KR, Menza MA, Fitz-Simmons A. Modafinil monotherapy in depression. Eur Psychiatry 2002; 17: 167-169
118. Ninan PT, Hassman HA, Glass SJ, McManus FC. Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue. J Clin Psychiatry 2004; 65: 414-420
119. Robertson P jr, Hellriegel ET. Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet 2003; 42: 123-137
120. Pöldinger W. Combined administration of desipramine and reserpine or tetrabenazine in depressive patients. Psychopharmacologia 1967; 11: 18-30
121. Hopkinson G, Kenney F. Treatment with reserpine of patients resistant to tricyclic antidepressants. Psychiatr Clin 1975; 8: 109-114
122. Moscovich D, Mester R. Tricyclic antidepressive treatment reinforced by reserpine. Isr J Psychiatr Rel Sci 1984; 21: 283-289
123. Amsterdam JD, Berwish N. Treatment of refractory depression with combination reserpine and tricyclic antidepressant therapy. J Clin Psychopharmacology 1987; 7: 238-242
124. Price LH, Chamey DS, Heninger GR. Reserpine augmentation of desipramine in refractory depression: clinical and neurobiological effects. Psychopharmacology 1987; 92: 431-437
125. Charney DS, Price LH, Heninger GR. Desipramine-Yohimbine combination treatment for refractory depression. Arch Gen Psychiatry 1986; 43: 1155-1161
126. Schmauß M, Laakmann G, Dieterle D. Effects of alpha-receptor blockade in addition to tricyclic antidepressants in therapy resistant depression. J Clin Psychopharmacol 1988; 8: 108-111
127. Rickels K, Amsterdam JD, Clary C et al. Buspirone in major depression: a controlled study. J Clin Psychiatry 1991; 52: 34-38
128. Jacobsen FM. Possible augmentation of antidepressant response by buspirone. J Clin Psychiatry 1991; 52: 217-230
129. Bakish D. Fluoxetine potentiation by buspirone: three case histories. Can J Psychiatry 1991; 36: 749-750
130. Joffe RT, Schuller DR. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J Clin Psychiatry 1993; 54: 269-271
131. Dimitriou EC, Dimitriou CE. Buspirone augmentation of antidepressant therapy. J Clin Psychopharmacol 1998; 18: 465-469
132. Landen M, Bjorling G, Agren H et al. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment refractory depression. J Clin Psychiatry 1998; 59: 664-668
133. Kemp LI. Sodium valproate as an antidepressant. Br J Psychiatry 1992; 160: 121-123
134. Ballenger JC. The clinical use of carbamazepine in affective disorders. J Clin Psychiatry 1988; 49 (Suppl): 13-19
135. Calabrese JR, Suppes T, Sachs GS. A double blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry 1999; 60: 79-88
136. Dietrich DE, Emrich HM. The use of anticonvulsants to augment anti-depressant medication. J Clin Psychiatry 1998; 59 (Suppl 5): 51-58
137. Boukoms A, Mangini L. Pergolide: an antidepressant adjuvant for mood disorders? Psychopharmacol Bull 1993; 29: 207-211
138. Michelson D, Bancroft J, Targum S et al. Female sexual dysfunction associated with antidepressant administration: a randomized, placebo-controlled study of pharmacologic intervention. Am J Psychiatry 2000; 157: 239-243
139. Inoue T, Tsuchiya K, Miura J et al. Bromocriptine treatment of tricyclic and heterocyclic antidepressant-resistant depression. Biol Psychiatry 1996; 40: 151-153
140. Sporn J, Ghaemi SN, Sambur MR et al. Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review. Ann Clin Psychiatry 2000; 12: 137-140
141. th Annual Meeting of the ACNP. San Juan, Puerto Rico: 2000; Dec 10-14
142. Dawson LA, Nguyen HQ. The role of 5-HAT(1A) and 5-HAT(1B/1D) receptors on the modulation of acute fluoxetine-induced changes in extracellular 5-HAT: the mechanism of action of (±) pindolol. Neuropharmacology 2000; 39: 1044-1052
143. Artigas F, Romero L, Montigny C de, Blier P. Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci 1996; 19: 378-383
144. Blier P, Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol 1995; 15: 217-222
145. Moreno FA, Gelenberg AJ, Bachar K et al. Pindolol augmentation of treatment-resistant depressed patients. J Clin Psychiatry 1997; 58: 437-439
146. Perez V, Soler J, Puigdemont D et al. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Arch Gen Psychiatry 1999; 56: 375-379
147. Olver JS, Cryan JF, Burrows GD et al. Pindolol augmentation of antidepressants: a review and rationale. Aust N Z J Psychiatry 2000; 34: 71-79
148. Spillmann M, Fava M. S-adenosylmethionine (Ademetionine) in psychiatric disorders: historical perspective and current status. CNS Drugs 1996; 6: 416-425
149. Alpert JE, Pingol MG, Rankin MA et al. Methylfolate as an adjunct in SSRI refractory depression. In: Syllabus and Proceedings Summary of the APA Meeting. Washington DC: May 15-20,1999; No 75: 32
150. Coppen A, Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial. J Affect Disord 2000; 60: 121-130
151. Warner MD, Peabody CA, Whiteford HA, Hollister LE. Alprazolam as an antidepressant. J Clin Psychiatry 1988; 49: 148-150
152. Petty F, Trivedi MH, Fulton M, Rush AJ. Benzodiazepines as antidepressants: does GABA play a role in depression? Biol Psychiatry 1995; 38: 578-591
153. Bauer M, Whybrow PC, Angst J et al. WFSBP-Guidelines for biological treatment of unipolar depressive disorders, Part 1: Acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 2002; 3: 5-43